Michael Yeaman from UCLA: Neuromyelitis Optica Treatment Making Great Strides
SEPTEMBER 16, 2016
There are currently no medications approved for the treatment of neuromyelitis optica (NMO). However, there are clinical trials underway and more research being done to change that in the coming years.
Michael R. Yeaman, PhD, from UCLA discussed the latest developments in the field during the annual ECTRIMS meeting in London. While a separate condition from multiple sclerosis (MS) Yeaman said a lot has been learned about NMO as a result of research on MS. Yeaman said the clinical trials being conducted in this field are providing excitement in the field that there may be ways to help patients in ways that were not available in years past. This includes the CIRCLES study thanks in part to the Guthy Jackson Charitable Foundation. If this work continues moving in a positive direction Yeaman said there could someday be a cure for NMO rather than just trying to find the right treatments at the present time.